urc102
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2013 (NCT01953497)
Timeline
Indications
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- urc102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05198778 | Phase 1 | Nov 29, 2021 | Chonbuk National University, JW Pharmaceutical |
| NCT02557126 | Phase 2 | Oct 1, 2015 | JW Pharmaceutical |
| NCT02524678 | Phase 1 | Aug 5, 2015 | JW Pharmaceutical, Seoul National University |
| NCT02290210 | Phase 2 | Jul 24, 2014 | JW Pharmaceutical |
| NCT01953497 | Phase 1 | May 23, 2013 | JW Pharmaceutical, Seoul National University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| JW Pharmaceutical | For profit | 5 | 5 | 2 | 2013 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1